Rational use of in vitro P-glycoprotein assays in drug discovery.
暂无分享,去创建一个
J. Polli | L. Huang | J. Humphreys | L. Webster | Liyue Huang | S. Wring | J W Polli | C. Serabjit-Singh | J. Morgan | S A Wring | J E Humphreys | L Huang | J B Morgan | L O Webster | C S Serabjit-Singh | Lindsey O. Webster | J. Morgan | L. O. Webster | L. Huang
[1] T. Litman,et al. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. , 1997, Biochimica et biophysica acta.
[2] F. Loor,et al. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. , 1996, Anti-cancer drugs.
[3] A. Seelig. A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.
[4] G. A. Scarborough. Drug-stimulated ATPase activity of the human P-glycoprotein , 1995, Journal of bioenergetics and biomembranes.
[5] M. Kool,et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.
[6] J. Schellens,et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. , 1999, Pharmacological research.
[7] J Ferté,et al. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. , 2000, European journal of biochemistry.
[8] G Ecker,et al. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. , 1999, Biochemical pharmacology.
[9] W. Kirch,et al. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.
[10] Y. Assaraf,et al. The Role of Passive Transbilayer Drug Movement in Multidrug Resistance and Its Modulation* , 1996, The Journal of Biological Chemistry.
[11] J. Beijnen,et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Larsson,et al. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. , 1994, Experimental cell research.
[13] M. Fromm,et al. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. , 2000, International journal of clinical pharmacology and therapeutics.
[14] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[15] P. Roepe,et al. The P-Glycoprotein Efflux Pump: How Does it Transport Drugs? , 1998, The Journal of Membrane Biology.
[16] K. Paull,et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. , 1997, Molecular pharmacology.
[17] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[18] A. Schinkel,et al. P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.
[19] M. Fromm,et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. , 2000, The Journal of pharmacology and experimental therapeutics.